|Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA||CEO, Pres & Director||866.77k||N/A||1972|
|Dr. Aya Jakobovits Ph.D.||Founder & Independent Director||43.51k||N/A||1953|
|Mr. Brian Nicholas Harvey||Chief Financial Officer||596.79k||N/A||1961|
|Dr. Francesco Galimi M.D., Ph.D.||Chief Medical Officer & Sr. VP||651.39k||N/A||1968|
|Dr. Donald Healey||Chief Technology Officer||N/A||N/A||1962|
|Dr. Blake Aftab Ph.D.||Sr. VP & Chief Scientific Officer||N/A||N/A||N/A|
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Adicet Bio, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 10.